Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Markus Moehler, Sang Cheul Oh et al.|The Lancet Oncology|2013Cited by 838
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Kenneth J. O’Byrne, Jose R. Pereira et al.|The Lancet Oncology|2011Cited by 574